ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/PPAR-alpha
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/PPAR-alpha
1
trial(s) found.
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA-4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ PPAR-alpha inhibitor
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (1)
Recruitment Country and State
NZ (1)
Phase
Phase 1 / Phase 2 (1)
Trial Type
Advanced (1)
Cancer Therapy Class
CTLA4
100%
HIF2a
100%
IL-6
100%
LAG3
100%
PD-1
100%
PD-1/PD-L1
100%
PD-L1
100%
PPAR-alpha
100%
TIGIT
100%
VEGF
100%
Facility
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
Cancer Type
Cancer
Gastrointestinal cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Solid tumour
Upper gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy